Anthony G. Quinn, President & CEO at Aeglea BioTherapeutics, Inc. (AGLE), bought 174,884 shares at $6.02 ($773K) on 2018-02-15, disclosed to the SEC on 2018-12-10.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.02 | 2,000 | $12K | 1.6% |
| 2 | $9.13 | 994 | $9K | 1.2% |
| 3 | $4.11 | 150,000 | $617K | 79.8% |
| 4 | $5.46 | 3,306 | $18K | 2.3% |
| 5 | $6.31 | 18,584 | $117K | 15.2% |
| Total | $4.42 avg | 174,884 |
| $773K |
| 100% |
| Filing → |
| AGLE | BUY | 2022-03-18 | $375K | — | Filing → |
| AGLE | BUY | 2022-03-15 | $562K | — | Filing → |
| AGLE | BUY | 2021-12-13 | $358K | — | Filing → |